| ID Source | ID |
|---|---|
| PubMed CID | 46867138 |
| CHEMBL ID | 1085857 |
| SCHEMBL ID | 17078239 |
| MeSH ID | M0578661 |
| Synonym |
|---|
| CHEMBL1085857 , |
| bdbm50318691 |
| 4-(piperidin-1-yl)-1,2,5-thiadiazol-3-yl piperidine-1-carboxylate |
| 1234569-09-5 |
| lalistat 2 |
| SCHEMBL17078239 |
| lalistat 2, >=98% (hplc) |
| AKOS032962874 |
| 4-(piperidin-1-yl)-1,2,5-thiadiazol-3-ylpiperidine-1-carboxylate |
| (4-piperidin-1-yl-1,2,5-thiadiazol-3-yl) piperidine-1-carboxylate |
| MS-24250 |
| EX-A6729 |
| HY-128144 |
| CS-0095363 |
| 1-piperidinecarboxylic acid 4-(1-piperidinyl)-1,2,5-thiadiazol-3-yl ester |
Lalistat 2 is a specific inhibitor of LAL which allows the determination of L AL in DBS.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Lalistat 2 is a specific inhibitor of LAL which allows the determination of LAL in DBS." | ( A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2. Galloway, P; Hamilton, J; Jones, I; Srivastava, R, 2012) | 1.32 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Lysosomal acid lipase/cholesteryl ester hydrolase | Homo sapiens (human) | IC50 (µMol) | 0.1520 | 0.1520 | 0.1520 | 0.1520 | AID482622 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| sterol esterase activity | Lysosomal acid lipase/cholesteryl ester hydrolase | Homo sapiens (human) |
| lipase activity | Lysosomal acid lipase/cholesteryl ester hydrolase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| fibrillar center | Lysosomal acid lipase/cholesteryl ester hydrolase | Homo sapiens (human) |
| nucleoplasm | Lysosomal acid lipase/cholesteryl ester hydrolase | Homo sapiens (human) |
| lysosome | Lysosomal acid lipase/cholesteryl ester hydrolase | Homo sapiens (human) |
| cytosol | Lysosomal acid lipase/cholesteryl ester hydrolase | Homo sapiens (human) |
| lysosomal lumen | Lysosomal acid lipase/cholesteryl ester hydrolase | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Lysosomal acid lipase/cholesteryl ester hydrolase | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Lysosomal acid lipase/cholesteryl ester hydrolase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID482628 | Inhibition of LAL in human GM05659 cell lysate assessed as reduction in lysosomal storage organelle cholesterol level at 0.1 to 10 uM treated for 3 days measured after 1 day of compound withdrawal by bicinchoninic acid assay | 2010 | Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14 | Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics. |
| AID482630 | Inhibition of LAL in intact human GM05659 cells assessed as increase in neutral lipid accumulation in lysosomal storage organelle at 10 uM after 3 days by lipidTox green staining-based fluorescence microscopy | 2010 | Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14 | Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics. |
| AID482631 | Cytotoxicity against human GM05659 cells at 10 uM | 2010 | Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14 | Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics. |
| AID482627 | Inhibition of LAL in human GM05659 cell lysate assessed as reduction in lysosomal storage organelle cholesterol level at 0.1 to 10 uM after 4 days by bicinchoninic acid assay | 2010 | Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14 | Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics. |
| AID482629 | Inhibition of LAL in intact human GM03123 cells assessed as reduction in lysosomal storage organelle cholesterol level at 10 uM after 3 days by filipin LSO assay | 2010 | Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14 | Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics. |
| AID482626 | Inhibition of human LAL assessed as enzyme decarbamoylation rate constant at 10 uM after 30 mins by fluorescence assay | 2010 | Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14 | Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics. |
| AID482625 | Inhibition of human LAL at 833 nM by fluorescence assay | 2010 | Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14 | Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics. |
| AID482632 | Cytotoxicity against human GM03123 cells at 10 uM | 2010 | Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14 | Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics. |
| AID482622 | Inhibition of human LAL after 30 mins by fluorescence assay | 2010 | Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14 | Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.74) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||